Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 2
Submit an article Journal homepage
85
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Effects of aspirin on cancer initiation and progression

Kevin S Choe Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. [email protected]
&
Stanley L Liauw Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
Pages 115-117 | Published online: 10 Jan 2014

References

  • Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat. Rev. 33(4), 358–368 (2007).
  • Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J. Clin. Oncol. 27(29), 4902–4911 (2009).
  • Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325(23), 1593–1596 (1991).
  • Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl Cancer Inst. 99(8), 608–615 (2007).
  • Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348(10), 883–890 (2003).
  • Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826), 1602–1612 (2012).
  • Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759), 31–41 (2011).
  • Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826), 1591–1601 (2012).
  • Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 30(28), 3540–3544 (2012).
  • Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J. Clin. Oncol. 28(9), 1467–1472 (2010).
  • Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9(5), 259–267 (2012).
  • Núñez L, Valero RA, Senovilla L,Sanz-Blasco S, García-Sancho J, Villalobos C. Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. J. Physiol. (Lond.) 571(Pt 1), 57–73 (2006).
  • Mahdi JG, Alkarrawi MA, Mahdi AJ, Bowen ID, Humam D. Calcium salicylate-mediated apoptosis in human HT-1080 fibrosarcoma cells. Cell Prolif. 39(4), 249–260 (2006).
  • Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94(4), 252–266 (2002).
  • Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356(21), 2131–2142 (2007).
  • Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576–590 (2011).
  • Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11(2), 123–134 (2011).
  • Dixon DA, Tolley ND, Bemis-Standoli K et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J. Clin. Invest. 116(10), 2727–2738 (2006).
  • Stone RL, Nick AM, McNeish IA et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366(7), 610–618 (2012).
  • Borsig L. The role of platelet activation in tumor metastasis. Expert Rev. Anticancer Ther. 8(8), 1247–1255 (2008).
  • Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61(1), 46–52 (1968).
  • Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1), 47–55 (2005).
  • Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85(3), 265–271 (2001).
  • McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119(8), 624–638 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.